Drug Trial Radar · NCT06041386
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
177
Actual
Start
Mar 20, 2024
Primary completion
Feb 12, 2026
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Sep 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, real-world, single arm, global, multi-centre study to evaluate the effect of timely treatment with mepolizumab (NUCALA) to achieve clinical remission in adult participants with severe asthma with an eosinophilic phenotype (SA-EP).
Conditions
- Asthma
Interventions
MepolizumabDrug
Mepolizumab will be prescribed based on physician decision.
SpirometryOther
Lung function via spirometry will be collected.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage (%) of Participants Achieving 4-Component Clinical RemissionTime frame: At month 12
Locations
65 sites in 9 countries. Site status is shown where the registry gives one.
GSK Investigational Site
La Jolla, California
GSK Investigational Site
Newport Beach, California
GSK Investigational Site
Aurora, Colorado
GSK Investigational Site
Colorado Springs, Colorado
GSK Investigational Site
New Haven, Connecticut
GSK Investigational Site
Homestead, Florida
GSK Investigational Site
Jacksonville, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Plantation, Florida
GSK Investigational Site
Adairsville, Georgia
GSK Investigational Site
Columbus, Georgia
GSK Investigational Site
Lexington, Kentucky
GSK Investigational Site
Owensboro, Kentucky
GSK Investigational Site
New Orleans, Louisiana
GSK Investigational Site
Glenn Dale, Maryland
GSK Investigational Site
Towson, Maryland
GSK Investigational Site
Ann Arbor, Michigan
GSK Investigational Site
Linwood, Minnesota
GSK Investigational Site
Rochester, Minnesota
GSK Investigational Site
Henderson, Nevada
GSK Investigational Site
Rochester, New York
GSK Investigational Site
Schenectady, New York
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Union, South Carolina
GSK Investigational Site
Cypress, Texas
GSK Investigational Site
Kerrville, Texas
GSK Investigational Site
McKinney, Texas
GSK Investigational Site
Kortrijk, Belgium
GSK Investigational Site
Liège, Belgium
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Winnipeg, Manitoba, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Brest, France
GSK Investigational Site
Cannes, France
GSK Investigational Site
Lille, France
GSK Investigational Site
Lyon, France
GSK Investigational Site
Strasbourg, France
GSK Investigational Site
Toulouse, France
Showing 40 of 65 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.